Single agent bevacizumab for myelofibrosis: Results of the myeloproliferative disorders research consortium trial

Ruben A. Mesa, Richard T. Silver, Srdan Verstovsek, John Mascarenhas, Craig M. Kessler, Damiano Rondelli, Judy D. Goldberg, Roberto Marchioli, Erin P. Demakos, Lewis R. Silverman, Ronald Hoffman

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

The myeloproliferative neoplasm, myelofibrosis, is a morbid and frequently fatal illness encompassing primary myelofibrosis, and end-stage essential thrombocythemia and polycythemia. Bevacizumab (15 mg/kg intravenous (i.v.) every 21 days) was tested in a phase II international trial conducted by the Myeloproliferative Disorders Research Consortium. Thirteen patients were enrolled in the first stage of this 2-stage trial. Among the 11 patients who received therapy, only 3 received more than 4 cycles of therapy; none of the patients achieved an objective response. Furthermore, significant toxicity, not directly related to the vascular or gastrointestinal events typically associated with the anti-VEGF monoclonal antibody preparation in other disease states, was observed. Lack of objective responses coupled with toxicity led to the decision to terminate the study early. If future studies incorporate bevacizumab in combination therapy for myelofibrosis, more modest doses should be considered.

Original languageEnglish (US)
Pages (from-to)1421-1423
Number of pages3
JournalHaematologica
Volume98
Issue number9
DOIs
StatePublished - Sep 1 2013

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Single agent bevacizumab for myelofibrosis: Results of the myeloproliferative disorders research consortium trial'. Together they form a unique fingerprint.

  • Cite this

    Mesa, R. A., Silver, R. T., Verstovsek, S., Mascarenhas, J., Kessler, C. M., Rondelli, D., Goldberg, J. D., Marchioli, R., Demakos, E. P., Silverman, L. R., & Hoffman, R. (2013). Single agent bevacizumab for myelofibrosis: Results of the myeloproliferative disorders research consortium trial. Haematologica, 98(9), 1421-1423. https://doi.org/10.3324/haematol.2012.083337